Hyperlipidemia

Rebecca L. Remillard, PhD, DVM, DACVN
Veterinary Nutritional Consultations
Hollister, North Carolina

Background
Hyperlipidemia is caused by increased plasma triglycerides, cholesterol, or both and is a normal postprandial finding; within 0.5 to 2 hours of consuming dietary fat, chylomicrons appear and remain in the blood for 6 to 10 hours. In a fasted (>12 hours) sample, hyperlipidemia is caused by a disturbance in the metabolism of the lipoprotein responsible for carrying hydrophobic fat to and from tissue (eg, intestine, muscle, adipose, liver). Therefore, hyperlipoproteinemia has been used interchangeably with hyperlipidemia when an abnormally high plasma lipoprotein is identified.

Increased fasted lipoprotein blood levels are associated with either an overproduction or decreased removal of the specific lipoprotein and the type of fat it carries. High blood concentrations of chylomicrons and very-low-density lipoprotein (VLDL) will appear as high plasma triglyceride levels, whereas high concentrations of high-density lipoprotein (HDL) and/or low-density lipoprotein (LDL) raise plasma cholesterol levels. Hypertriglyceridemia is more clinically relevant than hypercholesterolemia.

Primary lipoprotein metabolism disorders are relatively uncommon and associated with specific breeds (eg, miniature schnauzer, Shetland sheepdog, briard, rough collie, Doberman, rottweiler). Secondary hypertriglyceridemia is clinically more common and caused by several primary disorders. Endocrine disease (eg, diabetes mellitus [DM], hypothyroidism, hyperadrenocorticism), pancreatitis, obesity, protein-losing nephropathy (PLN), and cholestasis are known to cause or be associated with secondary hypertriglyceridemia.

Clinical Signs
Common, mild presentations of hypertriglyceridemia include intermittent episodes of vomiting, diarrhea, and abdominal pain or discomfort. The more severe presentations are pancreatitis (as a secondary or primary disorder), lipemia retinalis, cutaneous xanthomas, seizures, peripheral nerve paralysis (eg, tibial, radial, Horner syndrome), and behavioral changes. Less common presentations include splenomegaly, lipid keratopathy, anemia, and xanthelasma. Signs of DM, hypothyroidism, hyperadrenocorticism, pancreatitis, obesity, PLN, and/or cholestasis are also likely.

How I Treat Hyperlipidemia
- Treat hypertriglyceridemia (>500 mg/dL) present in a 12- to 18-hour fasted sample.
- Feed a low-fat (<30 g/Mcal*) diet with reevaluation in 6–8 weeks.
- Consider individual diet history.
- Consider concurrent diseases.
- Consider supplementing with fish oil containing EPA and DHA.
- Consider other possible treatments for lowering VLDLs.

DHA = docosahexaenoic acid, DM = diabetes mellitus, EPA = eicosapentaenoic acid, HDL = high-density lipoprotein, LDL = low-density lipoprotein, PLN = protein-losing nephropathy, VLDL = very-low-density lipoprotein

*1 Mcal (megacalorie) = 1000 kcal

September 2014 • Clinician’s Brief 85
Hyperlipidemia

**How I Diagnose**

- 12- to 18-hour fasted lipemic serum sample is suggestive of hypertriglyceridemia.²
  - Clear serum contains <200 mg/dL (2.26 mmol/L).
  - Turbid serum begins at 200–300 mg/dL (2.26–3.39 mmol/L).
  - Lactescent (milk-like) serum indicates ~1000 mg/dL (11.3 mmol/L).
  - Hypercholesterolemia does not cause an increase in serum turbidity because LDL and HDL do not refract light.

Refrigerate sample for 12 hours to determine if the hypertriglyceridemia was caused by chylomicrons or VLDL.
- Chylomicrons float to the top (ie, as a creamy layer).
- VLDL results in a uniformly turbid sample.
- A creamy layer over a cloudy serum layer indicates both are present.

Perform a heparin release test to assess activity level of lipoprotein lipase.
- A defect in endothelium lipoprotein lipase is suspected if there is no difference in the pre- and postheparin sample triglyceride concentration (heparin releases lipoprotein lipase and stimulates triglyceride hydrolysis).¹

Consider lipoprotein electrophoresis and ultracentrifugation to identify and quantify the lipoproteins, respectively.
- These are not routine.
- Normal ranges are not well defined.

**How I Treat**

- Treat hypertriglyceridemia (>500 mg/dL) present in a 12- to 18-hour fasted sample.
  - Secondary hypertriglyceridemia typically improves with correction of the primary metabolic disorder (eg, pancreatitis, DM, PLN).
  - Maintain a fasted triglyceride level of <400 mg/dL to minimize signs and complications.

- Feed a low-fat (<30 g/Mcal) diet; reevaluate in 6–8 weeks.
  - Fat content of low-fat diets expressed as a percentage of dry matter may not coincide with grams of fat/Mcal.
  - Compare products on a caloric basis (Tables 1 and 2).

- Consider individual diet history in diet selection.
  - If the patient currently eats a high-fat diet, recommend 20–30 g/Mcal diet initially.
  - If the patient is already on a fat-restricted diet (<30 g/Mcal), recommend changing to an ultra-low-fat diet (<10 g/Mcal) formulated by a nutritionist.

- Consider concurrent diseases.
  - For diabetic dogs and overweight diabetic cats, consider low-fat/high-fiber therapeutic diets.
  - For hyperlipidemic, underweight diabetics and PLN cases, commercial diet options are limited but highly specialized diets can be tailored by a nutritionist.

- Consider supplementing with fish oil containing EPA and DHA, as hypertriglyceridemia caused by disturbances in the metabolism of endogenous VLDL lipoproteins may not fully respond to a low-fat diet.
  - For dogs, the recommended omega-3 dose (70–100 mg/kg body weight) may be increased as needed up to the National Research Council safe upper limit (200 mg/kg body weight); no safe upper limit has been determined for cats.³
  - Pet foods may include omega-3 fatty acids; however, those using flaxseed meal or oil contain only ALA, and ALA–EPA conversion in dogs and cats is thought to be low (<10%).

---

ALA = alphanlinolenic acid, DHA = docosahexaenoic acid, DM = diabetes mellitus, DMB = dry matter basis, EPA = eicosapentaenoic acid, PLN = protein-losing nephropathy, VLDL = very-low-density lipoprotein
### Table 1  Canine Foods by Fat*

<table>
<thead>
<tr>
<th>Product</th>
<th>Fat g/Mcal</th>
<th>Fat % DMB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rayne Clinical Nutrition Low Fat Kangaroo (wet)</td>
<td>18.4</td>
<td>6.1</td>
</tr>
<tr>
<td>Royal Canin Veterinary Diet GI Low Fat (canned)</td>
<td>19</td>
<td>6.5</td>
</tr>
<tr>
<td>Hill's Pet Nutrition i/d Low Fat (dry)</td>
<td>20</td>
<td>7.4</td>
</tr>
<tr>
<td>Royal Canin Veterinary Diet GI Low Fat (dry)</td>
<td>20.1</td>
<td>7.1</td>
</tr>
<tr>
<td>Iam’s Weight Loss Mobility Plus (dry)</td>
<td>22.6</td>
<td>8.3</td>
</tr>
<tr>
<td>Hill’s Pet Nutrition i/d Low Fat (canned)</td>
<td>23</td>
<td>8.5</td>
</tr>
<tr>
<td>Purina Veterinary Diets OM Overweight Management (dry)</td>
<td>24</td>
<td>7.2</td>
</tr>
<tr>
<td>Hill’s Pet Nutrition r/d (dry)</td>
<td>25</td>
<td>8.2</td>
</tr>
<tr>
<td>Hill’s Pet Nutrition w/d (dry)</td>
<td>26</td>
<td>8.7</td>
</tr>
<tr>
<td>Purina Veterinary Diets HA (dry)</td>
<td>26</td>
<td>10.5</td>
</tr>
<tr>
<td>Hill’s Pet Nutrition r/d (canned)</td>
<td>29</td>
<td>8.6</td>
</tr>
<tr>
<td>Purina Veterinary Diets EN (dry)</td>
<td>30</td>
<td>12.4</td>
</tr>
<tr>
<td>Purina Veterinary Diets OM Overweight Management (canned)</td>
<td>34</td>
<td>10.5</td>
</tr>
<tr>
<td>Hill’s Pet Nutrition w/d (canned)</td>
<td>36</td>
<td>12.7</td>
</tr>
<tr>
<td>Iam’s Weight Loss Mobility Plus (canned)</td>
<td>38.1</td>
<td>16.09</td>
</tr>
<tr>
<td>Rayne Clinical Nutrition Moderate Protein Cod (wet)</td>
<td>42.6</td>
<td>17.05</td>
</tr>
<tr>
<td>Purina Veterinary Diets EN (canned)</td>
<td>41.3</td>
<td>17.8</td>
</tr>
</tbody>
</table>

*Sorted based on fat-per-calorie basis

### Table 2  Feline Foods by Fat*

<table>
<thead>
<tr>
<th>Product</th>
<th>Fat g/Mcal</th>
<th>Fat % DMB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Iam’s Weight Loss Mobility Plus (canned)</td>
<td>24.8</td>
<td>16.3</td>
</tr>
<tr>
<td>Purina Veterinary Diets OM Overweight Management (dry)</td>
<td>25</td>
<td>8.5</td>
</tr>
<tr>
<td>Hill’s Pet Nutrition r/d (dry)</td>
<td>26</td>
<td>8.7</td>
</tr>
<tr>
<td>Rayne Clinical Nutrition Low Fat Kangaroo (wet)</td>
<td>26.5</td>
<td>8.9</td>
</tr>
<tr>
<td>Hill’s Pet Nutrition w/d (dry)</td>
<td>27</td>
<td>9.1</td>
</tr>
<tr>
<td>Iam’s Weight Loss Mobility Plus (dry)</td>
<td>28.2</td>
<td>10.4</td>
</tr>
<tr>
<td>Royal Canin Veterinary Diet Calorie Control (dry)</td>
<td>29.5</td>
<td>10.6</td>
</tr>
<tr>
<td>Hill’s Pet Nutrition r/d (canned)</td>
<td>30</td>
<td>9.2</td>
</tr>
<tr>
<td>Royal Canin Veterinary Satiety Support (dry)</td>
<td>30.6</td>
<td>9.5</td>
</tr>
<tr>
<td>Royal Canin Veterinary Diet Calorie Control (3 oz canned)</td>
<td>31.3</td>
<td>11.2</td>
</tr>
<tr>
<td>Royal Canin Veterinary Diet GI Moderate Calorie (dry)</td>
<td>37.4</td>
<td>13.8</td>
</tr>
<tr>
<td>Royal Canin Veterinary Diet Calorie Control (5.8 oz canned)</td>
<td>37.5</td>
<td>13.7</td>
</tr>
<tr>
<td>Purina Veterinary Diets OM Overweight Management (canned)</td>
<td>38</td>
<td>13.1</td>
</tr>
<tr>
<td>Royal Canin Veterinary Diet GI Moderate Calorie (canned)</td>
<td>39.4</td>
<td>15.1</td>
</tr>
<tr>
<td>Royal Canin Veterinary Diet GI Fiber Response HF</td>
<td>40.7</td>
<td>15.9</td>
</tr>
<tr>
<td>Rayne Clinical Nutrition Cod and Sweet Potato (wet)</td>
<td>43</td>
<td>17.1</td>
</tr>
<tr>
<td>Hill’s Pet Nutrition w/d (canned)</td>
<td>48</td>
<td>16.6</td>
</tr>
</tbody>
</table>

*Sorted based on fat-per-calorie basis
Hypertriglyceridemia is caused by disturbances in the metabolism of the chylomicron and/or VLDL lipoprotein.

The disturbance in chylomicron and/or VLDL lipoprotein metabolism is more likely secondary to another ongoing disease process rather than a primary disorder, except in certain breeds.

Clinical signs can be intermittent and not specific to hyperlipidemia.

More severe presentations are more likely to be associated with well-described diseases (eg, endocrine disorders, pancreatitis, obesity, PLN, cholestasis).

Feeding a low-fat diet (≤20–30 g/Mcal) for 6–8 weeks is the first line of treatment with a fasted serum triglyceride goal <400 mg/dL.

Homemade diets with ultra-low-fat content (<10 g/Mcal) can be formulated on an individual basis by a nutritionist.

Supplementing with fatty acids (70–100 mg/kg) may be needed in cases of hyper-VLDL production.

Consider niacin (dogs, 100 mg PO q24h) and gemfibrozil (dogs, 7.5 mg/kg body weight PO q12h; cats, 10 mg/kg body weight PO q12h).^1^ Both have adverse effects and should be considered only when diet cannot maintain serum triglyceride <500 mg/dL.

Consider other possible treatments for lowering VLDLs.

Pet foods containing fish oil contain EPA and DHA but typically at low levels.

Supplementing with concentrated fish oil containing EPA and DHA is necessary for therapy.

See Aids & Resources, back page, for references & suggested reading.

DHA = docosahexaenoic acid, EPA = eicosapentaenoic acid, PLN = protein-losing nephropathy, VLDL = very-low-density lipoprotein

---

Verafl ox (pradofl oxacin) Oral Suspension for Cats

Oral Suspension for Cats

For the treatment of skin infections (wounds and abscesses) in cats. Do not use in dogs.

**HOW I TREAT**

**BRIEF SUMMARY:**

Before using Verafl ox Oral Suspension for Cats, please consult the product insert, a summary of which follows:

**CAUTION:**

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals.

**PRODUCT DESCRIPTION:**

Pradofl oxacin is a fluoroquinolone antibiotic and belongs to the class of quinolone carboxylic acid derivatives. Each mL of Verafl ox Oral Suspension provides 25 mg of pradofl oxacin.

**INDICATIONS:**

Verafl ox is indicated for the treatment of skin infections (wounds and abscesses) in cats caused by susceptible strains of Pasteurella multocida, Streptococcus canis, Staphylococcus aureus, Staphylococcus felis, and Staphylococcus pseudintermedius.

**CONTRAINDICATIONS:**

DO NOT USE IN DOGS. Pradofl oxacin has been shown to cause bone marrow suppression in dogs. Dogs may be particularly sensitive to this effect, potentially resulting in severe thrombocytopenia and neutropenia. Quinolone-class drugs have been shown to cause arthropathy in immature animals of most species tested, the dog being particularly sensitive to this side effect. Pradofl oxacin is contraindicated in cats with a known hypersensitivity to quinolones.

**HUMAN WARNINGS:**

Not for human use. Keep out of reach of children. Individuals with a history of quinolone hypersensitivity should avoid this product. Avoid contact with eyes and skin. In case of ocular contact, immediately flush eyes with copious amounts of water. In case of dermal contact, wash skin with soap and water for at least 20 seconds. Consult a physician if irritation persists following ocular or dermal exposure or in case of accidental ingestion. In humans, there is a risk of photosensitization within a few hours after exposure to quinolones. If excessive accidental exposure occurs, avoid direct sunlight. Do not eat, drink or smoke while handling this product. For customer service or to obtain product information, including a Material Safety Data Sheet, call 1-800-633-3766. For medical emergencies or to report adverse reactions, call 1-800-422-9674.

**ANIMAL WARNINGS:**

For use in cats only. The administration of pradofl oxacin for longer than 7 days induced reversible leukocyte, neutrophil, and lymphocyte decreases in healthy, 12-week-old kittens.

**PRECAUTIONS:**

The use of fluoroquinolones in cats has been associated with the development of retinopathy and/or blindness. Such products should be used with caution in cats. Quinolones have been shown to produce erosions of cartilage of weight-bearing joints and other signs of arthropathy in immature animals of various species. The safety of pradofl oxacin in cats younger than 12 weeks of age has not been evaluated. The safety of pradofl oxacin in immune-compromised cats (ie, cats infected with feline leukemia virus and/or feline immunodeficiency virus) has not been evaluated. Quinolones should be used with caution in animals with known or suspected central nervous system (CNS) disorders. In such animals, quinolones have, in rare instances, been associated with CNS stimulation that may lead to convulsive seizures. The safety of pradofl oxacin in cats that are used for breeding or that are pregnant and/or lactating has not been evaluated.

**ADVERSE REACTIONS:**

In a multi-site field study, the most common adverse reactions seen in cats treated with Verafl ox were diarrhea/loose stools, leukocytosis, elevated CPK levels, and sneezing.

**ANIMAL SAFETY:**

In a target animal safety study in 32, 12-week-old kittens dosed at 0, 1, 3, and 5 times the recommended dose for 21 consecutive days. One 3X cat and three 5X cats had absolute neutrophil counts below the reference range. The most frequent abnormal clinical finding was soft feces. While this was seen in both treatment and control groups, it was observed more frequently in the 3X and 5X kittens.

**U.S. Patent No. 6,323,213 May, 2012 84364593/84364607, R.0 NADA141-344, Approved by FDA Made in Germany Bayer, the Bayer Cross and Verafl ox are registered trademarks of Bayer. GHG041114 Bayer HealthCare LLC Animal Health Division Shawnee Mission, Kansas 66201, U.S.A.